Arch Biopartners Inc. (TSXV: ARCH)
Canada
· Delayed Price · Currency is CAD 1.950
+0.020 (1.04%)
Nov 22, 2024, 3:59 PM EST
Arch Biopartners Company Description
Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada.
It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys.
The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals.
Arch Biopartners Inc. is based in Toronto, Canada.
Contact Details
Address: 27 Street Clair Avenue East Toronto, M4T 2M5 Canada | |
| Phone | 647 428 7031 |
| Website | archbiopartners.com |
Stock Details
| Ticker Symbol | ARCH |
| Exchange | TSX Venture Exchange |
| Fiscal Year | October - September |
| Reporting Currency | CAD |
| ISIN Number | CA03938C1041 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard Gabriel Muruve | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Daniel Abraham Muruve M.D. | Co-Founder, Chief Science Officer and Member of Scientific Advisory Board |
| Andrew Bishop CFA | Chief Financial Officer and Director |
| Dr. Justin MacDonald Ph.D. | Co-Founder and Principal Scientist |
| Dr. Paul Beck | Co-Founder and Principal Scientist |
| Aaron Benson | Director of Communications |